Who Pays to Move?

Movement is financed through a patchwork of public programs, insurance, employers, philanthropy and household cash. The absence of a deliberate model is itself a policy choice.

Section I showed how the delay in establishing who pays kills patients operationally – the unsynchronized clocks of the clinical decision and the financial authorization. This piece asks the larger and unresolved question behind that delay: across the region as a whole, who actually should bear the cost of moving a patient to care – and why the absence of a clear answer is itself a systemic failure. Because the operational delay is, at bottom, a symptom. The disease is that the region has, in most cases, never decided how movement is financed, and so decides it the worst possible way: case by case, under pressure, at the moment of crisis.

The current reality is a patchwork, not a system.

The current reality is a patchwork, not a system.

Out-of-pocket. For a significant share of patients, the cost of movement falls directly on the family – and at the price points involved, particularly for charter and dedicated medevac, that is frequently a sum no family can produce on the timeline a crisis demands. When movement is out-of-pocket, the financing question and the survival question become the same question, decided by the patient’s bank balance.

Private insurance and medical-evacuation cover. Some patients are covered by insurance or dedicated medical-evacuation arrangements that finance movement – a genuine solution for those who hold it. But coverage of this kind is unevenly distributed, which means it solves the financing problem precisely for the population least likely to be unable to solve it otherwise, and not for the population most exposed. This is the medevac/insurance category’s legitimate relevance – and also the seam where access financing and access inequality become the same subject.

A region that has not decided how movement is financed has decided that whoever can pay will move.

Public health systems. Public systems finance some movement, but their capacity to do so is constrained, the rules are often unclear at the point of crisis, and the authority to commit funds may not be reachable when it is needed. A pathway that is funded in principle but cannot be authorized at 2 a.m. is not, operationally, funded.

The absence of a pooling mechanism means each patient faces the full cost alone, at the worst moment.

The missing regional layer. What the region largely lacks is any shared mechanism for financing movement – a regional risk pool, a cross-border financing arrangement, a standing fund for emergency transfers – that would spread the cost of an inherently variable, high-cost, low-frequency event across a larger base. Movement cost is, in actuarial terms, exactly the kind of risk that is ruinous to an individual and manageable across a pool. The absence of a pooling mechanism means each patient faces the full cost alone, at the worst moment.

The governance argument is that a region that has not decided how movement is financed has decided, by default, that it will be financed by whoever can pay at the time – which is the least equitable and most operationally dangerous arrangement available. The alternative is not a single model but a deliberate one: pre-agreed financing for defined emergency categories, clearer and faster authorization, and serious exploration of risk-pooling mechanisms that match the actuarial shape of the problem. None of this is simple, and the region does not have the fiscal space for easy answers. But the current non-decision is itself an answer, and it is the worst one – because it loads the entire, variable, sometimes-ruinous cost of survival onto individual families at the moment they are least able to bear it, and calls the result a system.

We take up the equity consequences of all this directly in Section VI. Here the point is structural: movement financing is the region’s great unsolved access problem, and it is unsolved largely because no one has been made responsible for solving it.

Sometimes the better investment moves expertise instead

The ANNOTeM teleneurology network was associated with improved 90-day outcomes without a substantial increase in per-patient costs; mean costs rose 2.6% and the increase was not statistically significant. This does not eliminate the need for transfer. It changes the comparator. Payers should evaluate the full pathway: moving the patient, moving expertise, building local capability or combining all three – including the costs of delay, family travel and failed continuity.


Share: